A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.
NCT ID: NCT00461006
Last Updated: 2016-08-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
176 participants
INTERVENTIONAL
2007-06-30
2008-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)
NCT01893242
A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril
NCT01398267
Acthar for Treatment of Proteinuria in Diabetic Nephropathy Patients
NCT01601236
Effect of Adding Renin-Angiotensin System Inhibitors to Standard Antidiabetic Therapy on Glycemic Control in Patients With Type 2 Diabetes Ellitus
NCT04707508
Renohemodynamic Effects of Combined empagliflOzin and LosARtan
NCT04238702
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Aleglitazar
aleglitazar
0.6mg po daily
Actos
Actos
45mg po daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Actos
45mg po daily
aleglitazar
0.6mg po daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* type 2 diabetes for \>=1 month;
* drug naive, or receiving stable oral antihyperglycemic medication;
* HbA1c 6.5-10.0% at screening.
Exclusion Criteria
* current or previous treatment with insulin;
* history of renal disease other than diabetic nephropathy;
* uncontrolled hypertension;
* clinically significant cardiovascular disease;
* Congestive heart failure (CHF) New York Heart Association (NYHA) 3-4.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peoria, Arizona, United States
Jonesboro, Arkansas, United States
Fresno, California, United States
Los Gatos, California, United States
Mission Viejo, California, United States
Jacksonville, Florida, United States
Omaha, Nebraska, United States
Charlotte, North Carolina, United States
Marion, Ohio, United States
Altoona, Pennsylvania, United States
Arlington, Texas, United States
Arlington, Texas, United States
Dallas, Texas, United States
Midland, Texas, United States
San Antonio, Texas, United States
Norfolk, Virginia, United States
Chihuahua City, , Mexico
Chihuahua City, , Mexico
Hermosillo, , Mexico
Metepec, , Mexico
Mexico City, , Mexico
Mexico City, , Mexico
Mexico City, , Mexico
Monterrey, , Mexico
Zapopan, , Mexico
ManatÃ, , Puerto Rico
Ponce, , Puerto Rico
Toa Baja, , Puerto Rico
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Moscow, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Saratov, , Russia
Tyumen, , Russia
Yaroslavl, , Russia
Dnipro, , Ukraine
Dnipro, , Ukraine
Donetsk, , Ukraine
Donetsk, , Ukraine
Kharkiv, , Ukraine
Kharkiv, , Ukraine
Kiev, , Ukraine
Kiev, , Ukraine
Kiev, , Ukraine
Lugnansk, , Ukraine
Poltava, , Ukraine
Ternopil, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BC20653
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.